MYLAN-VARDENAFIL 5 MG
VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) : 5 MG · DIN 02464209 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is MYLAN-VARDENAFIL?
MYLAN-VARDENAFIL 5 MG contains VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02464209, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Nov-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02464209 |
|---|---|
| Brand name | MYLAN-VARDENAFIL |
| Generic / active ingredient | VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) : 5 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BE09 VARDENAFIL |
| AHFS class | 24:12.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Nov-2018 |
| Original market date | 2018-11-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code G04BE09 VARDENAFIL. 12 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-VARDENAFIL | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02471655 |
| APO-VARDENAFIL | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02471663 |
| APO-VARDENAFIL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02471647 |
| JAMP-VARDENAFIL | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02475685 |
| JAMP-VARDENAFIL | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02475693 |
| JAMP-VARDENAFIL | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02475677 |
| JAMP-VARDENAFIL ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | JAMP PHARMA CORPORATION | MARKETED | DIN 02476088 |
| MYLAN-VARDENAFIL | 10 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02464225 |
| MYLAN-VARDENAFIL | 20 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02464233 |
| VARDENAFIL | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02520397 |
Who else supplies VARDENAFIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VARDENAFIL appears in 38 registered pack listings across 6 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.